Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 6, 2026, Rocket One Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.…

Other Events. On July 31, 2026, Rocket One Inc. (the “Company”) increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated November 8, 2024, to up to an additional aggregate of $5,257,000, which does not include the approximately $13,557,905 of shares of Common Stock that were sold to date pursuant…

Other Events. Rocket One Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after July 21, 2026, in presentations about the Company’s operations and performance. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the Presentation Materials is summary information that should be considered within the context of the Company’s filings with…

Other Events. On June 3, 2026, Rocket One Inc. (the “Company”) increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated November 8, 2024, to up to an additional aggregate of $6,829,000, which does not include the approximately $9,279,067 of shares of Common Stock that were sold to date pursuant to…

Other Events. On May 27, 2026, Rocket One Inc. (the “Company”) increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated November 8, 2024, to up to an additional aggregate of $2,661,176, which does not include the approximately $6,618,059 of shares of Common Stock that were sold to date pursuant to…

Entry into a Material Definitive Agreement. On May 15, 2026 (the "Effective Date"), Rocket One Inc. (“Rocket One”), a newly formed subsidiary of Hoth Therapeutics, Inc. (the “Company”), entered into two exclusive license agreements (collectively, the “VCU License Agreements”) with the Virginia Commonwealth University Intellectual Property Foundation (“VCU”) as further described below. Pursuant to the License Agreements, VCU granted Rocket One an exclusive, royalty-bearing license to certain p…

Other Events. On April 22, 2026, Hoth Therapeutics, Inc. (the “Company”) filed Articles of Incorporation with the Secretary of State of the State of Nevada for the formation of its new wholly-owned subsidiary, Rocket One Inc. (“Rocket One”). Rocket One was formed to acquire, own and operate assets related to the space industry, including nano rocket systems for the deployment of nanosatellites. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K includes “forw…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 30, 2026, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid pric…

Other Events. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2026, Hoth Therapeutics, Inc. (the “Company”) suspended its use of and terminated the prospectus supplement and related prospectus relating to the potential issuance from time to time of the Company’s common stock pursuant to the At the Market Offering Agreement, dated November 8, 2024 by and between the Company and H.C. Wainwright & Co., LLC (the “S…

Other Events. Press Releases On April 1, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. On April 2, 2026, the Company issued a press release announcing the closing of the Offering. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K. ATM Agreement On April 1, 2026, the Company suspended the use of its prospectus supplement and related prospectus filed with the SEC…

Entry into a Material Definitive Agreement. On April 1, 2026, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,144 shares (the “Shares”) of common stock of the Company (the “Common Stock”), at a purchase price of $0.70 per share of Common Stock (the “Offering”). The shares of Common Stock were offered by the Company pursuant…

by reference. The Warrants and the Placement Agent Warrants and the shares issuable upon exercise of the Warrants and Placement Agent Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.

Other Events. Hoth Therapeutics, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after January 16, 2026, for meetings with US government officials for its weight loss drug and its therapeutics pipeline. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the Presentation Materials is summary information that should be considered with…

Other Events. On September 10, 2025, Hoth Therapeutics, Inc.’s (the “Company’s”) board of directors approved the expansion of the Company’s previously announced treasury reserve strategy to include Ethereum and Solana. As such, the Company may purchase up to $1 million in Bitcoin, Ethereum and/or Solana as a treasury reserve asset, provided that the aggregate cost of such purchases does not exceed 20% of the Company’s cash on hand at the time of purchase. Risk Factors The Company is supplemen…

Chief Executive Officer and President — Robb Knie: Mr. Knie's role and responsibilities were reaffirmed with a new employment agreement.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 13, 2025, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price…

Director — Graig Springer: Mr. Springer resigned from the Board and related committees.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. During the preparation of our 2024 audited consolidated financial statements and notes thereto, we concluded that there were material errors related to recording of prepaid research and development and the timing of the related research and development expense in our previously issued audited consolidated financial statements as of and for the years ended December 31, 2023, and in our…

Entry into a Material Definitive Agreement. On March 24, 2024, Hoth Therapeutics, Inc. (“Hoth” or the “Company”) entered into a Project Order Agreement (the “Agreement”) with OnTargetx R&D Inc. (“OnTargetx”) pursuant to the terms of an existing Master Service Agreement originally entered into on November 8, 2024, Under the Agreement, OnTargetx, in collaboration with ITR Laboratories, will perform a 4-week intravenous injection toxicity study followed by a 14-day recovery period in C57BL/6 mic…

Other Events. On February 7, 2025, Hoth Therapeutics, Inc. (the “Company”) increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., dated November 8, 2024, to up to an additional aggregate of $5,000,000, which does not include the approximately $2,700,000 of shares of common stock that were sold to date purs…

Other Events. On November 20, 2024, Hoth Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company’s board of directors approved the Company’s purchase of up to $1 million in Bitcoin as a treasury reserve asset. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. Risk Factors The Company is supplementing the risk factors previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023 with the followin…

Entry into a Material Definitive Agreement. On November 8, 2024, Hoth Therapeutics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), under which the Company may offer and sell shares of its common stock, par value $0.0001 per share, (the “Shares”), having an aggregate sales price of up to $2,700,000 through Wainwright as the sales manager. Sales of shares of the Company’s common stock through Wainwright…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 30, 2024, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid pr…

On March 27, 2024, Hoth Therapeutics, Inc., a Nevada corporation (the “ Company ”), entered into an inducement offer letter agreement (the “ Inducement Letter ”) with a certain holder (the “ Holder ”) of existing warrants (the “ Existing Warrants ”) to purchase shares of common stock of the Company. The Existing Warrants were issued on January 3, 2023, and had an exercise price of $5.00 per share. Pursuant to the Inducement Letter, the Holder agreed to exercise for cash their Existing Warrant…

Unregistered Sales of Equity Securities. The Company issued the New Warrants and the Placement Agent Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the New Warrants, the Placement Agent Warrants nor the New Warrant Shares or the shares of common stock issuable upon the exercise of the Placement Agent Warrants have been registered under the Securities Act and such securities may not be offered…